KEY FINDINGS The North America pulmonary drug delivery market is estimated to harbor a CAGR of 4.40%, during the forecast years of 2019 to 2028. The primary factors propelling the market growth include, advanced technology and affordability, the increased geriatric population, and the rising prevalence of lifestyle-related diseases and other respiratory conditions. MARKET INSIGHTS The North America pulmonary drug delivery market growth is assessed across the United States and Canada. According to the Statistics of Canada, over 260,000 patients in Canada, within the age bracket of 50 to 64, suffered from chronic obstructive pulmonary disease (COPD) in 2016. Over the next year, this figure increased to more than 314,000 patients. Similarly, according to the Ontario Lung Association, asthma accounts for at least 80% of the total chronic respiratory disorders in the country. Moreover, the Asthma Society of Canada has also declared an overall surge in the number of people, especially children, with asthma. On the other hand, non-profit organizations, namely, the Canadian Thoracic Society and COPD Canada, are endeavoring to create awareness regarding alternative treatment methods for asthma as well as COPD. Such initiatives encourage patients to discover and explore innovative options, while subsequently providing lucrative opportunities to the region’s pulmonary drug delivery market. Additionally, the mesh nebulization technology is establishing itself as a standard of care in several medical facilities across the country. As a result, benefits such as potential cost-saving and superior performance further drive the region’s market growth. COMPETITIVE INSIGHTS Key players operating in the market are, 3M Company, GF Health Products Inc, Agilent Technologies Inc, Novartis AG, Teva Pharmaceutical Industries Ltd, etc. Our report offerings include: • Explore key findings of the overall market • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges) • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions • Market Segmentation cater to a thorough assessment of key segments with their market estimations • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc. • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc. • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments